Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
eIF2Bα CRISPR Activation Plasmid (h): sc-404034-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- eIF2Bα CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- eIF2Bα CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by eIF2Bα CRISPR Activation Plasmid (h) and eIF2Bα CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the EIF2B1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: eIF2Bα Antibody (C-11): sc-376846
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
eIF2Bα CRISPR Activation Plasmid (h) | sc-404034-ACT | 20 µg | $397.00 |
EIF2B1 encodes the eIF2Bα regulatory subunit of eukaryotic translation initiation factor 2B (eIF2B), a guanine nucleotide exchange factor that reactivates eIF2 by catalyzing GDP-to-GTP exchange. eIF2B integrates signaling from the integrated stress response (ISR), linking eIF2α phosphorylation to global translation attenuation and selective translation of stress-responsive mRNAs during ER stress, nutrient limitation, and viral challenge. By controlling translation initiation rates, eIF2Bα influences proteostasis, cell survival decisions, and metabolic adaptation. Dysregulation of eIF2B activity is associated with neurodevelopmental and neurodegenerative phenotypes, including EIF2B-related leukodystrophies, making EIF2B1 a valuable node for studying stress signaling and translational control in human cells.
eIF2Bα CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous EIF2B1 expression without altering the underlying DNA sequence.
eIF2Bα CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the EIF2B1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the EIF2B1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous eIF2Bα expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native EIF2B1 locus and enabling the study of eIF2Bα-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of eIF2Bα pathway restoration in tumor cells with silenced or reduced EIF2B1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.